<DOC>
	<DOCNO>NCT00810147</DOCNO>
	<brief_summary>The purpose study determine safety tolerability BMS-708163 patient mild moderate Alzheimer 's disease treatment period 12-weeks course potential effect 12-week wash-out period</brief_summary>
	<brief_title>A Phase II , Multicenter , Double Blind , Placebo-Controlled Safety , Tolerability Study BMS-708163 Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Clinical diagnosis Mild Moderate Alzheimer 's disease ( MMSE 1626 ) 6 Month cognitive decline Stable market AD therapy x2 month additional market AD therapy study Score &lt; =4 Modified Hachinski Ischemia Scale CT result consistent Alzheimer 's disease Medically stable 6 year education Reliable study partner ( caregiver ) Must able swallow capsule Premenopausal woman Dementia due cause Alzheimer 's disease History stroke Immunocompromised Active peptic ulcer , GI bleed , chronic inflammatory bowel disease , chronic diarrhea past GI surgery would impact drug absorption Unstable Vitamin B12 deficiency Hematologic solid malignancy within 5 year Geriatric Depression Scale &gt; = 6 Unstable medical condition Alcohol drug abuse history 12months study entry Significant drug allergy Alzheimer 's disease modification experimental therapy 12 month study entry Prisoners , compulsory psychiatric patient , resident nurse home skilled nursing facility entry Any experimental therapy 30days study entry</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>